Technology
Health
Pharmaceutical

Axsome Therapeutics

$13.00
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.24 (-1.81%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell AXSM and other stocks, options, ETFs, and crypto commission-free!

About

Axsome Therapeutics, Inc. Common Stock, also called Axsome Therapeutics, is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Read More Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Employees
29
Headquarters
New York, New York
Founded
2012
Market Cap
391.13M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
726.33K
High Today
$13.46
Low Today
$12.51
Open Price
$13.35
Volume
633.23K
52 Week High
$14.24
52 Week Low
$1.94

Collections

Technology
Health
Pharmaceutical
Therapy
Medical
Biopharmaceutical
2015 IPO
US

News

MarketWatchMar 22

Harry Boxer: 3 biotech stocks with momentum

Biotech stocks dominate our list of top charts to watch today. Axsome Therapeutics Inc. AXSM, -1.81% (AXSM) jumped $1.23 to $13.24 on 1.9 million shares Thursday. The stock is up over 50% this month, and over 400% since the start of the year, as investors await important clinical trial results on the company’s treatment for depression. The stock is a little overbought in the short term — down only once in the last three weeks — but momentum is strong for a move toward $16. Support is at the March 19 low in...

6
Seeking AlphaMar 14

Axsome Therapeutics, Inc. 2018 Q4 - Results - Earnings Call Slides

The following slide deck was published by Axsome Therapeutics, Inc. in conjunction with their 2018 Q4 earnings call. 1 41 Click to enlarge Notes:...

379
Associated PressMar 14

Axsome Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

Company to host conference call today at 8:00 AM Eastern NEW YORK, March 14, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the fourth quarter and year ended December 31, 2018. “In 2018, we advanced our clinical programs and significantly expanded our CNS pipeline through the addition of new internally generated product...

130

Earnings

-$0.34
-$0.29
-$0.24
-$0.19
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.30 per share
Actual
-$0.32 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.